These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 31206526)

  • 1. Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells.
    Eto S; Saeki K; Yoshitake R; Yoshimoto S; Shinada M; Ikeda N; Kamoto S; Tanaka Y; Kato D; Maeda S; Tsuboi M; Chambers J; Uchida K; Nishimura R; Nakagawa T
    PLoS One; 2019; 14(6):e0218382. PubMed ID: 31206526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
    Quinn DI; Tsao-Wei DD; Twardowski P; Aparicio AM; Frankel P; Chatta G; Wright JJ; Groshen SG; Khoo S; Lenz HJ; Lara PN; Gandara DR; Newman E
    Invest New Drugs; 2021 Jun; 39(3):812-820. PubMed ID: 33409898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorinostat exhibits anticancer effects in triple-negative breast cancer cells by preventing nitric oxide-driven histone deacetylation.
    Palczewski MB; Kuschman HP; Bovee R; Hickok JR; Thomas DD
    Biol Chem; 2021 Mar; 402(4):501-512. PubMed ID: 33938179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
    Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
    Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
    Sampson ER; Amin V; Schwarz EM; O'Keefe RJ; Rosier RN
    J Orthop Res; 2011 Apr; 29(4):623-32. PubMed ID: 20957741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid.
    Wu JC; Jiang HM; Yang XH; Zheng HC
    Cancer Med; 2018 Sep; 7(9):4554-4569. PubMed ID: 30091530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
    Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I
    J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.
    Pan CH; Chang YF; Lee MS; Wen BC; Ko JC; Liang SK; Liang MC
    BMC Cancer; 2016 Nov; 16(1):857. PubMed ID: 27821078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer.
    Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K
    Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
    Sampson VB; Vetter NS; Kamara DF; Collier AB; Gresh RC; Kolb EA
    PLoS One; 2015; 10(11):e0142704. PubMed ID: 26571493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
    Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
    BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
    Kurundkar D; Srivastava RK; Chaudhary SC; Ballestas ME; Kopelovich L; Elmets CA; Athar M
    Toxicol Appl Pharmacol; 2013 Jan; 266(2):233-44. PubMed ID: 23147569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
    Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD
    Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines.
    Sakai K; Maeda S; Saeki K; Nakagawa T; Murakami M; Endo Y; Yonezawa T; Kadosawa T; Mori T; Nishimura R; Matsuki N
    Vet Comp Oncol; 2018 Dec; 16(4):642-649. PubMed ID: 30246405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
    Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
    Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.